1. Apoptosis Metabolic Enzyme/Protease Immunology/Inflammation NF-κB Autophagy TGF-beta/Smad
  2. Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)
  3. Curdione

Curdione  (Synonyms: 莪术二酮; (+)-Curdione)

目录号: HY-N0353 纯度: 99.92%
COA 产品使用指南 技术支持

Curdione ((+)-Curdione) 是一种具有口服活性的倍半萜类物质。Curdione 抑制血小板聚集。Curdione 通过 METTL14 和 YTHDF2 介导的 m6A 甲基化在结直肠癌中诱导铁死亡 (ferroptosis)。Curdione 通过调控 Keap1/Trx1/GPX4 信号通路,抑制氧化应激 (ROS) 和细胞凋亡 (apoptosis) 抑制 Isoproterenol (HY-B0468) 诱发的心肌梗死中的铁死亡 (ferroptosis)。Curdione 通过抑制氧化应激 (ROS) 和激活 Nrf2/HO-1 通路来改善 Doxorubicin (HY-15142) 诱导的心脏毒性。Curdione 通过抑制血小板介导的中性粒细胞细胞外陷阱形成来改善败血症引起的肺损伤。Curdione 通过抑制 TGF-β 诱导的成纤维细胞向肌成纤维细胞分化来改善 Bleomycin (HY-17565A) 诱导的肺纤维化。Curdione 对大鼠局灶性脑缺血再灌注损伤具有神经保护作用。Curdione 通过靶向 IDO1 诱导对人子宫平滑肌肉瘤的抗增殖作用。Curdione 通过调节 DNMT1 介导的 ERBB4 启动子甲基化保护血管内皮细胞和动脉粥样硬化。Curdione 抑制诱导型前列腺素 E2 产生 (IC50 = 1.1 μM) 和环氧合酶 2 表达。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Curdione

Curdione Chemical Structure

CAS No. : 13657-68-6

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥351
In-stock
1 mg ¥135
In-stock
5 mg ¥341
In-stock
10 mg ¥535
In-stock
25 mg ¥923
In-stock
50 mg ¥1438
In-stock
100 mg ¥2188
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Curdione:

MCE 顾客使用本产品发表的 1 篇科研文献

查看 Heme Oxygenase (HO) 亚型特异性产品:

查看 TGF-β Receptor 亚型特异性产品:

查看 Indoleamine 2,3-Dioxygenase (IDO) 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC50 = 1.1 μM) and cyclooxygenase 2 expression[1][2][3][4][5][6][7][8][9][10][11][12].

体外研究
(In Vitro)

Curdione (12.5-50 μM, 48 小时) 可降低 CT26 细胞活力,促进细胞内 ROS 生成,增加 METTL14 和 YTHDF2 的表达水平,并降低 SLC7A11、SLC3A2、HOXA13 和 GPX4 的表达水平[1]
Curdione (12.5-50 μM, 48 小时) 可降低 CT26 和 SW480 细胞中的 GSH 浓度,增加 MDA、m6A、亚铁和 LPO 水平,并增加 SLC7A11 和 HOXA13 的 mRNA 水平[1]
Curdione (50 μM, 48 小时) 在 shRNA-METTL14 CT26 和 SW480 细胞中可降低细胞 ROS 浓度、Fe2+ 和 MDA 水平,增加 GSH 活性,并通过 m6A 修饰诱导铁死亡 XC 系统和的甲基化转移酶METTL14[1]
Curdione (12.5-50 μM,48 小时) 在 SW480 细胞中诱导细胞凋亡,其凋亡抑制剂 (Z-VAD-FMK (HY-16658B)) 对铁死亡无影响[1]
Curdione (25-100 μM,24 小时) 可提高 Isoproterenol (ISO) (HY-B0468) 诱导的 H9c2 细胞的存活率,减轻 Erastin (HY-15763) 诱导的 H9c2 细胞的细胞损伤[2]
Curdione (25-100 μM,24 小时) 与 Keap1 结合,调节 H9c2 细胞中的 Keap1/Trx1/GPX4 信号通路[2]
Curdione (100-200 μM) 可抑制小鼠骨髓中分离的中性粒细胞在接受 Phorbol 12-myristate 13-acetate (PMA) (HY-18739) 或化脓性血小板刺激后形成中性粒细胞胞外陷阱 (NET)。[3]
Curdione (160-500 μM,48 小时) 不影响细胞活力,抑制成纤维细胞分化为肌成纤维细胞,并抑制 HPF 中的 TGF-β/Smad3 信号传导[5]
Curdione (0-500 μM,12-72 小时) 在 SK-UT-1 和 SK-LMS-1 细胞中可降低细胞活力,抑制抑制 IDO1 介导的增殖,IC50 分别为 327 和 309.9 μM[7]
Curdione (0-100 μM,24 小时) 诱导 SK-UT-1 和 SK-LMS-1 细胞中 IDO1 介导的 G2/M 期停滞、细胞凋亡和自噬[7]
Curdione (0-200 μg/mL,72 小时) 诱导细胞凋亡,损害 MCF-7 细胞中的线粒体膜电位 (IC50 = 125.632 μg/mL)[9]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: CT26 cells
Concentration: 12.5 μM, 25 μM, 50 μM
Incubation Time: 48 h
Result: Increased the expression levels of METTL14 and YTHDF2, and decreased the expression levels of SLC7A11, SLC3A2, HOXA13, and GPX4.

Western Blot Analysis[1]

Cell Line: shRNA-METTL14 CT26 and SW480 cells
Concentration: 50 μM
Incubation Time: 48 h
Result: Increased expression of SLC7A11, HOXA13, SLC3A2 and GPX4.

Apoptosis Analysis[1]

Cell Line: SW480 cells
Concentration: 12.5 μM, 25 μM, 50 μM
Incubation Time: 48 h
Result: Inducted apoptosis, promoted the development of ferroptosis.
Had no statistically significant difference of ferroptosis when combined with Z-VAD-FMK (HY-16658B) (10 μM).

Western Blot Analysis[2]

Cell Line: H9c2 cells
Concentration: 100  μmol/L
Incubation Time: 1 h
Result: Increased the stability of Keap1.

Western Blot Analysis[2]

Cell Line: H9c2 cells/ Flag-Keap1, HA-GPX4, and Myc-Trx1 plasmids and tranfected to 293T cells
Concentration: 25 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: Inhibited Keap1 expression and increased ISO-induced Trx1 expression, reduced interaction between Keap1 and Trx1 and increased complex between Trx1 and GPX4.

Western Blot Analysis[5]

Cell Line: HPFs
Concentration: 160 μM, 300 μM
Incubation Time: 48 h
Result: Reduced fibronectin, collagen 1, and α-SMA levels.
Attenuated TGF-β1-induced p-Smad3 activation, but not p-Smad2.

RT-PCR[5]

Cell Line: HPFs
Concentration: 160 μM, 300 μM
Incubation Time: 48 h
Result: Reduced fibronectin, collagen 1, and α-SMA levels, increased Smad7 inhibits p-Smad3

Immunofluorescence[5]

Cell Line: HPFs
Concentration: 160 μM, 300 μM
Incubation Time: 48 h
Result: Reduced fibronectin, collagen 1, and α-SMA levels.

Immunofluorescence[7]

Cell Line: SK-UT-1 and SK-LMS-1 cells
Concentration: 0 μM, 25 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: Reduced the expression of EdU and Ki67.

Cell Cycle Analysis[7]

Cell Line: SK-UT-1 and SK-LMS-1 cells
Concentration: 0 μM, 25 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: Induced G2/M phase arrest.

Western Blot Analysis[7]

Cell Line: SK-UT-1 and SK-LMS-1 cells
Concentration: 0 μM, 25 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: Up-regulated the cell cycle checkpoint proteins P21 and CyclinB1 and down-regulated Cdc2.
Increased cleavage of caspase 3, 6, and 9 without affecting caspase 8.
Up-regulateed LC3 and Beclin-1, and down-regulated P62, IDO1.

Apoptosis Analysis[7]

Cell Line: SK-UT-1 and SK-LMS-1 cells
Concentration: 0 μM, 25 μM, 50 μM, 100 μM
Incubation Time: 24 h
Result: Increased the percentage of early and late apoptotic cells and induced cell death.

Apoptosis Analysis[9]

Cell Line: MCF-7 cells
Concentration: 0, 25, 50, 100, 150, 200 μg/mL
Incubation Time: 72 h
Result: Induced apoptosis, increased the expressions of Bax, cleaved caspase-3 and caspase-9, decreased Bcl-2 expression.
体内研究
(In Vivo)

Curdione (50-200 mg/kg,静脉注射,每日一次,22 天) 在 CRC 异种移植裸鼠中可抑制肿瘤生长,并通过 METTL14 和 YTHDF2 诱导由 m6A 甲基化介导的铁死亡[1]
Curdione (25-100 mg/kg,灌胃,每日一次,共 7 天) 在 ISO 诱导的心肌梗死 (MI) 雄性小鼠模型中可减轻心肌损伤,并通过调节 Keap1/Trx1/GPX4 信号通路缓解铁死亡[2]
Curdione (50-100 mg/kg,腹腔注射,一次) 在盲肠结扎穿刺 (CLP) 脓毒症小鼠模型中可改善肺损伤,降低炎症和氧化应激水平,抑制 MAPK 激酶和 NF-κB P65 的激活,肺中性粒细胞浸润和 NET 形成,调节血小板活化,并减少中性粒细胞与血小板的相互作用[3]
Curdione (100 mg/kg,腹腔注射,每 2 天一次,共 21 天) 在 Bleomycin (BLM) (HY-17565A) 诱导的特发性肺纤维化 (IPF) 小鼠模型中可减轻肺纤维化,降低纤维化特异性标志物的表达,并抑制成纤维细胞分化为肌成纤维细胞[5]
Curdione (100 mg/kg,腹腔注射,每天一次,共 7 天) 在动脉闭塞 (MCAO) SD 大鼠模型中通过抗氧化和抗凋亡作用,对脑缺血/再灌注引起的脑损伤发挥神经保护作用[6]
Curdione (100-200 mg/kg,腹腔注射,每日一次,共 21 天) 通过靶向 IDO1 并激活细胞凋亡和自噬来抑制 SK-UT-1 异种移植模型中的 uLMS 生长[7]
Curdione (50-150 mg/kg,每两天一次,共 16 天) 可抑制 MCE-7 异种移植 BALB/c 裸鼠模型中的肿瘤生长[9]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CRC (0.5 × 107, CT26 cells) xenograft nude mice[1]
Dosage: 50 mg/kg, 100 mg/kg, 200 mg/kg
Administration: i.v., once a day, 22 days
Result: Suppressed tumor volume and mass, exhibited pronounced ruffling and nuclear chromatin boundary setting, accompanied by necrosis and fibrosis, and decreased cell density.
Increased iron, MDA, and LPO levels, and decreased GSH levels.
Increased protein expression of METTL14, YTHDF2, SLC7A11, and decreased protein expression levels of SLC3A2, HOXA13, and GPX4.
Increased mRNA expression of YTHDF2, SLC7A11, SLC3A2, HOXA13, and PTGS2 and decreased mRNA expression of GPX4.
Animal Model: ISO (100 mg/kg)-induced MI C57BL/6 mice (21-25 g, 6-8 weeks) model[2]
Dosage: 25 mg/kg, 50 mg/kg, 100 mg/kg
Administration: i.g., once a day, 7 days
Result: Improved ejection fraction (EF), reduced ISO-increased CK-MB levels, restored normal muscle fiber structure, and reduced the degree of inflammatory cell infiltration in cardiac tissue.
Lowered MDA and iron levels and increaseed GSH, GPX4, FTH1 levels.
Inhibited Keap1 expression and increased ISO-induced Trx1 expression.
Animal Model: CLP sepsis mice (8-10 weeks old, Male) model[3]
Dosage: 50 mg/kg, 100 mg/kg
Administration: i.p., once
Result: Reduced lung congestion, alveolar wall thickening, and inflammatory cell infiltration in lung sections, reduced lung injury scores, pulmonary edema, and reduced exudate protein levels in BALF and lung W/D ratio, as well as LDH activity in BALF.
Reduced CLP-induced increases in DHE and MDA, increased superoxide dismutase (SOD) levels, and decreased IL-1β, IL-6, and TNF-α levels in BALF.
Inhibited the phosphorylation of MAPK kinase and NF-κB P65, and reduced the activation of NF-κB P65.
Reduced CXCL4 and CXCL7 in BALF and reduced platelet activation in lung tissue.
Decreased MPO-positive neutrophils, total cell counts in BALF, and the number of infiltrating neutrophils in BALF.
Reduced fluorescence intensity of platelet activation markers CD42d/GP5, neutrophil marker Ly6G and the formation of NETs in the lungs.
Animal Model: BLM-induced IPF mouse (8 weeks old, male) model[5]
Dosage: 100 mg/kg
Administration: i.p., every 2 days, 21 days
Result: Reduced lung injury, lung fibrosis, and inflammatory cell (lymphocyte and macrophage) infiltration levels, reduced hydroxyproline content.
Reduced protein and mRNA expression levels of fibronectin, collagen 1, and α-SMA.
Reduced α-SMA positive cells and reduced fibroblast differentiation.
Animal Model: MCAO SD rats (240-270 g, adult male) model[6]
Dosage: 100 mg/kg
Administration: i.g., once a day, 7 days
Result: Reduced infarct size and neurological deficits and promoted motor function and cognitive function recovery.
Reversed the obvious pathological abnormalities of the MCAO group, including loose arrangement of neurons, nuclear consolidation, loss of color staining or dark color.
Increased the activities of SOD, CAT and GSH-PX, suppressed the increase in the MDA content caused by the injury with cerebral ischemia/reperfusion.
Down-regulated Bax expression and up-regulated Bcl-2 expression, thereby increasing the Bcl-2/Bax ratio, reduced Cyt-C, c-caspase-3, and c-caspase-9 protein levels.
Animal Model: SK-UT-1 (1 × 107) xenograft BALB/c nude mice (6-7 weeks, female, 18 g) model[7]
Dosage: 100 mg/kg, 200 mg/kg
Administration: i.p., once a day, 21 days
Result: Exhibited anti-uLMS growth efficacy with minimal systemic toxicity, down-regulated IDO1, ki67, and p62, and up-regulated the cleaved caspase-3, Beclin1 and LC3 in tumor tissues.
Animal Model: MCE-7 (1 × 107) xenograft BALB/c nude mice (5-6 weeks, female, 20 g) model[9]
Dosage: 50 mg/kg, 100 mg/kg, 150 mg/kg
Administration: every two days, 16 days
Result: Inhibited tumor growth.
分子量

236.35

Formula

C15H24O2

CAS 号
性状

固体

颜色

White to off-white

中文名称

莪术二酮;姜黄二酮;莪二酮

结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
细胞实验: 

DMSO 中的溶解度 : 100 mg/mL (423.10 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.2310 mL 21.1551 mL 42.3101 mL
5 mM 0.8462 mL 4.2310 mL 8.4620 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.75 mg/mL (11.64 mM); 澄清溶液

    此方案可获得 ≥ 2.75 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

    生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.75 mg/mL (11.64 mM); 澄清溶液

    此方案可获得 ≥ 2.75 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

    2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。
动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
请输入您的动物体内配方组成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
连续给药周期超过半月以上,请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.92%

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.2310 mL 21.1551 mL 42.3101 mL 105.7753 mL
5 mM 0.8462 mL 4.2310 mL 8.4620 mL 21.1551 mL
10 mM 0.4231 mL 2.1155 mL 4.2310 mL 10.5775 mL
15 mM 0.2821 mL 1.4103 mL 2.8207 mL 7.0517 mL
20 mM 0.2116 mL 1.0578 mL 2.1155 mL 5.2888 mL
25 mM 0.1692 mL 0.8462 mL 1.6924 mL 4.2310 mL
30 mM 0.1410 mL 0.7052 mL 1.4103 mL 3.5258 mL
40 mM 0.1058 mL 0.5289 mL 1.0578 mL 2.6444 mL
50 mM 0.0846 mL 0.4231 mL 0.8462 mL 2.1155 mL
60 mM 0.0705 mL 0.3526 mL 0.7052 mL 1.7629 mL
80 mM 0.0529 mL 0.2644 mL 0.5289 mL 1.3222 mL
100 mM 0.0423 mL 0.2116 mL 0.4231 mL 1.0578 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Curdione
目录号:
HY-N0353
需求量: